Table IV.
Scoring of 15-PGDH protein and mRNA levels and COX-2 protein levels in gastric cancer at different stages with or without H. pylori infection.
| H. pylori-positive, n | H. pylori-negative, n | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Cancer stage | Total | 15-PGDH protein | 15-PGDH mRNA | COX-2 +/− | Total | 15-PGDH protein | 15-PGDH mRNA | COX-2 +/− | P-valuea |
| I–II | 11 | 1.79±083 | 0.69±0.26 | 10/1 | 12 | 2.47±1.10 | 1.07±0.46 | 8/4 | <0.05 |
| III–IV | 22 | 0.81±0.36 | 0.27±0.11 | 22/0 | 21 | 1.32±0.53 | 0.42±0.17 | 14/7 | <0.05 |
| P-valueb | <0.01 | <0.01 | <0.01 | <0.01 | |||||
a
Comparison between H. pylori-positive and -negative samples
b
comparison between stage I–II and stage III–IV samples. 15-hydroxy prostaglandin dehydrogenase; COX-2, cyclooxygenase-2; H. pylori, Helicobacter pylori.